- Home
- SSP vs TVRD Comparison
SSP vs TVRD Comparison
Compare SSP & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- TVRD
- Stock Information
- Founded
- SSP 1878
- TVRD 2017
- Country
- SSP United States
- TVRD United States
- Employees
- SSP N/A
- TVRD N/A
- Industry
- SSP Broadcasting
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- TVRD Health Care
- Exchange
- SSP Nasdaq
- TVRD Nasdaq
- Market Cap
- SSP 264.1M
- TVRD 246.5M
- IPO Year
- SSP 1988
- TVRD N/A
- Fundamental
- Price
- SSP $2.91
- TVRD $33.88
- Analyst Decision
- SSP Buy
- TVRD Strong Buy
- Analyst Count
- SSP 2
- TVRD 5
- Target Price
- SSP $5.50
- TVRD $59.20
- AVG Volume (30 Days)
- SSP 593.0K
- TVRD 21.2K
- Earning Date
- SSP 11-03-2025
- TVRD 08-14-2025
- Dividend Yield
- SSP N/A
- TVRD N/A
- EPS Growth
- SSP N/A
- TVRD N/A
- EPS
- SSP 0.48
- TVRD N/A
- Revenue
- SSP $2,439,152,000.00
- TVRD N/A
- Revenue This Year
- SSP N/A
- TVRD N/A
- Revenue Next Year
- SSP $10.24
- TVRD N/A
- P/E Ratio
- SSP $6.14
- TVRD N/A
- Revenue Growth
- SSP 5.25
- TVRD N/A
- 52 Week Low
- SSP $1.36
- TVRD $8.13
- 52 Week High
- SSP $4.17
- TVRD $36.71
- Technical
- Relative Strength Index (RSI)
- SSP 46.80
- TVRD 66.16
- Support Level
- SSP $2.75
- TVRD $29.33
- Resistance Level
- SSP $3.13
- TVRD $31.88
- Average True Range (ATR)
- SSP 0.16
- TVRD 2.09
- MACD
- SSP -0.01
- TVRD 0.49
- Stochastic Oscillator
- SSP 28.57
- TVRD 69.21
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.